Serious adverse events in academic critical care research

Abstract
Although it might be ideal to have a single system for defining and reporting serious adverse events that would be applicable to both academic trials investigating established drugs and industry-sponsored trials of novel pharmaceutical agents, such a system would be unlikely to satisfy all

This publication has 13 references indexed in Scilit: